entertainment -WSS

entertainment

author：hotspot 2025-09-14 14:45:01 - browse：282

After earning her doctorate in cell biology at the University of Pennsylvania in June, Sierra Collins did what many freshly minted Ph.D.s. do — she went looking for a job at a biotech company. But what was supposed to be a straightforward search has turned into an odyssey.

Collins has applied for more than 53 positions (and counting). Like a good scientist, she’s gathering data along the way and uses a spreadsheet to track each company’s size and therapeutic focus, as well as whether she was referred for the position and how far she made it through the application process. So far, those efforts have been unsuccessful.

“I try my best not to take it personally. These are companies that are trying to find an employee who’s going to help them achieve their business goals,” Collins said. “But it is pretty discouraging just repeatedly getting turned down, especially at later stages of the interview process.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Bird flu reported in person exposed to presumably infected cattle

hotspot

WSS

Oral obesity drug from Viking Therapeutics hits key early target

Republican states more likely to report Covid vaccine side effects

Overprescribed: High cost isn't America's only drug problem

New documents shed light on MD Anderson Cancer Institute feud

Antivenom research: Lessons from HIV applied in search for universal antidote

Insurer loopholes limit power of law against surprise medical bills

focus

entertainment

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Mass General Brigham physicians react to latest merger step

Supreme Court strikes down use of affirmative action

Medicare inequities exacerbate Puerto Rico’s health disparities

Continuity nursing helped my family in our darkest PICU moments

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Tori Bowie and the unacceptable rates of Black maternal death

R1 RCM gets $5.8 billion buyout offer from private equity firm

The cancer drug shortage isn’t new — and neither are the solutions

Young boy dies in trial for Pfizer Duchenne gene therapy

focus

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Gut bacteria may contribute to kidney autoimmunity, study finds

Covid silver lining: Unprecedented look at human immune system

6 phony surgeries that take placebo to the extreme

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

First Opinion on colorectal cancer screening: letter and response

hotspot

focus

hotspot

focus